BMJ

Complex systems approach for sports injuries: moving from risk factor identification to injury pattern recognition—narrative review and new concept

Correspondence to Dr ST Fonseca, Graduate Program in Rehabilitation Science, Physical Therapy Department, Universidade Federal de Minas Gerais, Minas Gerais, Avenida Presidênte Antônio Carlos, ...
Yahoo Finance

Should J.P. Morgan’s REC-4881 Upgrade and TUPELO Data Require Action From Recursion (RXRX) Investors?

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investing

Recursion Pharmaceuticals stock upgraded by JPMorgan on MEK inhibitor potential

Investing.com - JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) from Neutral to Overweight on Wednesday, while raising its price target to $11.00 from $10.00. The stock currently trades at ...
Yahoo Finance

Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data Release - What's Changed

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
manilatimes

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
Psychology Today

Steven Pinker on the Recursive Loop That Made Us Human

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
STAT

Merck’s RSV drug approval and a drug manufacturer winds down

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Nasdaq

Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...
manilatimes

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...
BioSpace

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
Pharmaceutical Technology

Recursion Pharmaceuticals gets grant for machine learning methods for biological perturbation data analysis

Recursion Pharmaceuticals. has been granted a patent for a method that employs machine learning to analyze perturbation data from various biological experiments. The process involves generating, ...